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Abstract
Purpose—To assess the efficacy and safety of 5-fluorouracil (5FU) and gemcitabine
administered concurrently with radiation in patients with locally advanced, non-metastatic
pancreatic cancer.
Patients and Methods—Eligible patients had histologically confirmed pancreatic
adenocarcinoma, deemed locally unresectable without evidence of metastatic disease. In addition,
all patients underwent laparoscopy or laparotomy prior to study entry to rule out peritoneal
carcinomatosis. Patients received radiation therapy (50.4 Gy) with concurrent infusional 5FU (200
mg/m2, 5 days per week) and weekly gemcitabine (200 mg/m2). After a three-week break, patients
received weekly gemcitabine at 1000 mg/m2 for 3 of 4 weeks, for four cycles. The primary
endpoint of the trial was the proportion of patients surviving nine months from study entry.
Secondary endpoints included objective tumor response, CA19-9 response, overall survival (OS)
time to progression (TTP) and toxicity.
Results—Between November 2001 and October 2004, 81 patients were enrolled, of whom 78
were eligible for analysis. With a median follow-up of 55.2 months, the median OS was 12.2
months (95% CI, 10.9 – 14.9 months) and median TTP was 10.0 months (95% CI 6.4 – 12.0
months). An objective tumor response was seen in 19 patients (25%) and among 56 patients with
an elevated CA19-9 at baseline, 29 (52%) had a sustained CA19-9 response. Overall, 41% of
patients had grade 3 or greater treatment-related GI adverse events.
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Conclusion—The combination of 5FU, gemcitabine and radiation is well-tolerated. Survival is
comparable to the best results of other recent studies of 5FU and radiation or gemcitabine and
radiation.
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INTRODUCTION
Pancreatic cancer, the fourth leading cause of cancer death in the United States1, remains
one of the most treatment-refractory solid malignancies. Approximately 40% of patients
with newly diagnosed pancreatic cancer present with locally advanced, non-metastatic
disease.
In two randomized trials by the Gastrointestinal Tumor Study Group, the combination of
fluorouracil and external beam radiation was shown to be more effective than either
modality alone, with a median overall survival of approximately 42 weeks2–4. An Eastern
Cooperative Oncology Group (ECOG) study, however, failed to demonstrate an advantage
to combined modality therapy5. The French FFCD-SFRO trial suggested a detriment in
survival when combined chemoradiation therapy was compared to gemcitabine alone6.
However, in this intensive regimen increased toxicity may have contributed to the poor
outcome. Despite these conflicting results, efforts over the past three decades have
attempted to improve the efficacy of chemoradiation, largely by incorporating more active
systemic therapy.
Among patients with metastatic or locally advanced pancreatic cancer, gemcitabine therapy
has led to a superior clinical benefit when compared to 5-fluorouracil (5FU) 7. As
gemcitabine has been shown to enhance the sensitivity of human pancreatic cancer cells to
radiation8, 9 several investigators have assessed the impact of gemcitabine when combined
with radiation. Most investigators combined lower doses of gemcitabine with conventional
radiation10–20. An alternative approach has been to combine full-dose gemcitabine with a
hypofractionated course of radiation21–23. Several groups have combined radiation and
gemcitabine with additional agents, including cisplatin24–29, oxaliplatin30, taxanes31, 32,
irinotecan33, mitomycin34 and inhibitors of EGFR and VEGF35–39.
As 5-FU and gemcitabine are both active radiation sensitizing agents and represent the two
principal systemic agents for pancreatic cancer, we conducted a phase I/II trial combining
5FU, gemcitabine and radiation in patients with locally advanced disease. The regimen
appeared well-tolerated with maximum tolerated doses of 200 mg/m2/day for infusional 5FU
and 200 mg/m2/week for gemcitabine with 50.4 Gy of radiation. More recently, Wilkowski
reported a similar experience in a group of 32 patients, with a median survival of over 13
months40. In contrast, a similar phase I study of concurrent 5-FU, gemcitabine and radiation
led by ECOG reported unacceptable toxicity41. Five of the seven treated subjects
experienced dose-limiting toxicities, three of which involved GI bleeding. To clarify the
safety and efficacy of this combination, we conducted a multi-institutional phase II trial of
5FU, gemcitabine and external beam radiation therapy in patients with locally advanced
pancreatic cancer.
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Eligible patients had biopsy-proven, localized, unresectable adenocarcinoma of the pancreas
and an ECOG performance score of 0 – 2. Criteria for unresectability and eligibility
included one or more of the following: a tumor measuring greater than 5 cm, regional lymph
nodes greater than 2 cm in size that could be included within the radiation port, involvement
of major vessels including the superior mesenteric artery, superior mesenteric vein, portal
vein or hepatic artery, and direct extension of tumor to adjacent organs. Staging studies
included a chest x-ray and an abdominal/pelvic CT scan; patients underwent a laparotomy or
laparoscopy to rule out the presence of occult peritoneal disease. Exclusion criteria included
a prior malignancy other than non-melanoma skin cancer or in-situ cervical cancer within
the past five years, or other major co-morbidities such as myocardial infarction within six
months of study entry. Required laboratory values included a total bilirubin below 2.0 mg/
dl, and AST ≤ 3x upper limits of normal, creatinine ≤ 2.0 mg/dl, WBC ≥ 3,000/mm3 and
platelets ≥ 100,000/mm3. All patients signed a consent form, and the study was approved by
the Human Investigations Committee of participating Cancer and Leukemia Group B
(CALGB) institutions.
Study Design and Treatment Plan
This was an open-label, non-randomized phase II study. Cycle one consisted of radiation to
50.4 Gy in 28 fractions over 5.5 weeks, with 5FU given as a continuous infusion from
Monday through Friday at 200 mg/m2/day and gemcitabine given weekly at 200 mg/m2,
both given throughout the radiation therapy course. Three weeks following the completion
of radiation, patients received gemcitabine at a dose of 1000 mg/m2 over 30 minutes weekly
for three weeks, followed by a one-week rest, for four 4-week cycles.
Radiation was delivered on a linear accelerator with a minimum energy of 6 MV. Patients
were simulated on a machine that reproduced the geometry of the treatment machine; multi-
field techniques were mandatory. Doses were specified to isocenter. Patients were treated to
4500 cGy in 25 fractions to an initial tumor / nodal field, followed by a boost field for an
additional 540 cGy in 3 fractions. The gross tumor volume (GTV) included the pancreatic
mass and any lymph nodes measuring > 1.5 cm as visualized on CT scan. The clinical target
volume (CTV) was defined by expanding the GTV for 1 to 1.5 cm, including the porta
hepatic and pancreaticoduodenal nodes for head lesions, and the celiac axis for tumors of
both the head and body/tail. The planning target volume (PTV) was based on a 1 cm
expansion of the CTV. The boost volume consisted of the GTV with a 1 cm expansion for
the boost PTV. Normal tissue constraints included no portion of the spinal cord receiving
above 4500 cGy, no more than 50% of the combined renal volume receiving above 2000
cGy and no more than 1/3 of the total liver volume receiving above 3000 cGy. All treatment
plans were reviewed by the Quality Assurance Review Center (QARC) in Providence, RI,
and by the study chair.
Dose Modifications for Adverse Events
Adverse events were scored using version 2.5 of the Common Terminology Criteria for
Adverse Events. During cycle 1, a decrease in platelets to between 50,000–99,999/mm3 and/
or a decrease in the ANC to 500–999/mm3 resulted in a 75% dose-reduction for gemcitabine
and a 50% dose-reduction for 5FU. If the ANC decreased below 500/mm3 or the platelets
decreased below 50,000/mm3, then chemotherapy and radiation were held until the ANC
was greater than or equal to 1,000/mm3 and the platelet count was above 100,000/mm3. If
treatment was held for greater than three weeks, the patient was removed from protocol
treatment.
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For non-hematologic events, both gemcitabine and 5FU were reduced to 75% of the dose for
grade 3 toxicity and to 50% of the dose for grade 4 toxicities. Reduced doses of
chemotherapy were not re-escalated. Owing to concerns about GI bleeding raised by ECOG
229742 stopping rules dictated study termination if more than 10 cases of grade 3 or higher
GI bleeding were observed among the first 35 patients. The incidence of bleeding was
followed in cohorts of seven patients, with plans to stop accrual if any of the following
proportions of patients had grade 3 or higher GI bleeds: 5 of 7, 6 of 14, 7 of 21, 9 of 28 or 11
of 35.
During cycles 2–5 (gemcitabine alone), the dose of gemcitabine was reduced by 25% for an
ANC between 500 and 999/mm3 and held for an ANC below 500/mm3. For grade 3 non-
hematologic toxicities gemcitabine was held and re-started at a 25% dose reduction when
the toxicity had resolved. For grade 4 non-hematologic adverse events, the gemcitabine was
held and re-started at a 50% dose reduction when the toxicity had resolved. Dose reductions
were continued through all subsequent cycles of gemcitabine.
Patient Monitoring
Patients were assessed weekly by history and physical examination. Laboratory studies,
including blood counts, BUN, creatinine, bilirubin, AST, alkaline phosphatase and CA19-9
were obtained weekly during combined chemoradiation and prior to each subsequent cycle
of gemcitabine. Blood counts were assessed prior to each weekly administration of
gemcitabine.
Statistical Considerations
The primary endpoint was the proportion of patients surviving nine months. Secondary
endpoints included overall survival (OS), measured from study entry to death from any
cause, time-to-tumor progression (TTP) measured from study entry to documented
progression of disease or death from any cause, CA19-9 response defined as ≥ 75%
decrease from the baseline maintained for two consecutive measurements at least four weeks
apart among patients with an elevated baseline CA19-9, and toxicity. The prior protocol for
patients with locally advanced pancreatic cancer, CALGB 89805, studied concurrent
gemcitabine (40 mg/m2 twice weekly) and radiation therapy in a similar patient population.
Based on the median survival of 8 months in that study17, it was determined that a median
survival of 9 months or less in the current protocol would be considered unworthy of further
investigation. An accrual goal of 78 evaluable patients to be followed for a minimum of 9
months was targeted resulting in 80% power to distinguish between median survival rates of
9 and 13 months. If the 90% lower confidence bound estimate (90% LCB) for the proportion
of patients surviving 9 months were to exceed 0.5, the regimen would be considered for
further investigation.
Patient registration and data collection were managed by the CALGB Statistical Center.
Data quality was ensured by careful review of data by CALGB Statistical Center staff and
by the study chairperson. All analyses were based on the study database frozen on March 3,
2009 and performed by CALGB statisticians using SAS 9.1 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
Eighty-one patients from 15 U.S. institutions were accrued between November 2001 and
October 2004, of whom 78 were eligible for analysis. Three patients who canceled their
registration prior to starting any protocol treatment were excluded from the analysis. Pre-
treatment characteristics of the eligible patients are shown in Table 1. Thirty-six percent of
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patients underwent palliative bypass surgery prior to starting treatment, 47% underwent the
placement of a biliary stent. The majority of patients had T4 tumors with vascular
involvement.
Efficacy
The median survival of the 78 eligible patients was 12.2 months (Table 2, Fig. 1) with four
patients reported alive at 39, 52, 58 and 60 months of follow-up. The estimated one-year
survival was 51% (95% CI 0.4 – 0.62). The 90% lower confidence bound for the proportion
of patients surviving 9 months was 0.64. The Kaplan-Meier survival estimate at 9 months
was 73% (95% CI 0.62 – 0.82). The probability of being progression free (Table 2, Fig. 2)
was 0.54 (95% CI 0.42 – 0.64) at 9 months and 0.40 (95% CI 0.29 – 0.50) at 1 year. Median
TTP was 10 months (95% CI 6.4 – 12.0).
Of the 56 patients with an elevated serum CA19-9 level at study baseline, 29 (52%)
experienced a sustained CA19-9 response, defined as a greater than 75% decrease lasting for
at least two measurements more than four weeks apart. When compared to patients who did
not experience a sustained CA19-9 response, subjects with a sustained response exhibited a
trend toward improved OS (median, 13 vs. 9 months; P = 0.11) and a statistically significant
improvement in TTP (median, 12.3 vs. 5.7 months, P = 0.007) (Figs. 3–4). Based on
RECIST criteria, 19 patients (24%) experienced an objective response, of whom 5 (6%) had
a complete response and 14 (18%) had a partial response. The median response duration was
5.5 months, with a minimum and maximum duration of 1 and 52.2 months, respectively
(including 12 patients with progressive disease and 4 patients who died without documented
progression). In addition, 41 (53%) had stable disease as their best response, 14 (18%) had
progressive disease and 4 patients (5%) were unevaluable. The median time to objective
response was 3.6 months (range 1.7 – 9.0).
Patterns of Failure
Twenty-eight (36%) of the patients had local progression in the pancreas as the first site of
failure. The next most common site of disease progression was in the liver, which occurred
in 23 (30%) of patients, followed by the lung (10%) and peritoneum (9%).
Treatment Modifications
Twenty-seven patients (35%) completed all protocol therapy. The most common reason for
stopping treatment was progressive disease, which occurred in 21 (27%) patients. Nine
(12%) discontinued treatment because of adverse events. Other common reasons for
discontinuing protocol treatment included being switched to non-protocol therapy (9%) and
patient refusal (9%).
A total of 64 patients (82%) had at least one treatment modification during the course of
therapy at a mean of 22 days after starting protocol treatment. Twenty-two patients had a
single dose modification. The maximum number of dose adjustments was 5 in two patients.
Radiotherapy Quality Assurance
All of the radiation therapy treatment plans were reviewed by QARC (Quality Assurance in
Radiation Oncology) in Providence, RI, and by the study chair. Major deviations were
defined as field borders that transected the gross tumor (GTV) or potentially tumor bearing
areas (CTV). In addition, a dose discrepancy of more than 10% above or below the
recommended dose at the prescription point, or exceeding the recommended dose to
adjacent critical organs was considered a major deviation. Of the 78 patients who started
radiation therapy, 65 cases were scored as appropriate, three had major deviations and seven
had minor deviations. The remaining 3 cases were unevaluable due to insufficient data
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provided. Sixty-eight patients (87%) completed the planned 28 fractions to a total dose of
5040 cGy. Ten patients discontinued radiation, one each after 3, 4, 13, 21, 22, and 24
fractions, two each after 25 and 26 fractions.
Adverse Events
Among the 78 patients, 55 (71%) experienced grade 3 or higher non-hematological adverse
events possibly attributed to treatment and 50 (64%) patients experienced grade 3 or higher
related hematologic adverse events (Table 3). The most common non-hematologic events
were gastrointestinal in 32 (41%) subjects, and constitutional and metabolic/laboratory each
in 19 (24%).
Without regard to attribution, 11 patients (14%) had at least one episode of gastrointestinal
bleeding during the study or follow-up period, of which five were considered grade 3 or
higher and possibly related to treatment. Neither a palliative surgical bypass nor placement
of a stent correlated with an increased risk of GI bleeding. Five of these 11 gastrointestinal
hemorrhages were localized within the radiation field.
Sixty-five (88%) of the deaths in the study population were secondary to disease
progression. Two deaths (2%) were considered to be treatment-related, resulting from
gastrointestinal bleeding in one subject and sepsis without neutropenia in the second. Three
deaths resulted from causes other than treatment or disease.
DISCUSSION
The benefit for treating locally advanced, non-metastatic pancreatic cancer remains limited,
with median survival ranging from eight to ten months43. In the current study of 78 patients,
a combination of gemcitabine and 5FU with radiation therapy conferred a median OS of
12.2 months and a median TTP of 10 months. In a previous phase I/II trial of gemcitabine,
5-FU and concurrent radiation therapy, we similarly observed a median survival of 12
months in patients with locally advanced disease. These results compare favorably to prior
studies of 5-FU with radiation, which reported a median OS of nine months and a median
TTP of eight months or less.
Following the initial studies of 5-FU and radiation therapy in locally advanced pancreatic
cancer, subsequent studies have also yielded median survivals well above the historical level
of nine months. This gradual improvement in outcome over the past several years is
apparent for both studies of radiation with gemcitabine10, 11, 14, 15, 17–23, 44 and for
other chemoradiation combinations3, 27, 39, 40, 45–50. The reasons for this improvement
are speculative, but may include slightly improved treatment regimens, improved staging
which excluded patients with not easily apparent metastatic disease, improved supportive
care, and improved salvage chemotherapy.
The current trial found the combination of 5FU and gemcitabine with concurrent radiation to
be tolerable, though toxicity was moderate. Twelve percent of patients discontinued protocol
therapy due to adverse events and 82% had at least one treatment modification. Our
incidence of adverse events was comparable to other recent cooperative group trials in this
patient population including a study of radiation with concurrent capecitabine and
bevacizumab39 and a trial of radiation with concurrent gemcitabine and cisplatin29. In
contrast to a prior ECOG trial51, the incidence and severity of gastrointestinal bleeding was
manageable.
Our trial met its target of 50% of patients surviving for at least 9 months; 9-month survival
was 73% and median overall survival was 12.2 months. A similarly designed trial of 32
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patients combining higher doses of weekly gemcitabine and infusional 5-FU with radiation,
followed by gemcitabine and cisplatin, observed a median OS of 13.6 months, although
toxicity in that trial was considerable40.
The merits of combined chemoradiation as initial treatment for locally advanced pancreatic
cancer have been questioned by the results of a recent randomized trial that demonstrated a
superior outcome for patients receiving gemcitabine alone compared to chemoradiation
followed by gemcitabine6. An alternative approach has been examined in which patients
receive initial chemotherapy, with chemoradiation offered only to those patients without
disease progression. In one retrospective study of 188 patients who had received three
months of initial chemotherapy, 128 patients who did not demonstrate progressive disease
received either further chemotherapy or combined chemoradiation. Although such non-
randomized data must be interpreted with caution, the median progression free survival and
OS for the patients receiving chemoradiation were 10.8 and 15 months, respectively,
compared to 7.4 and 11 months for those treated with chemotherapy alone52. Other
investigations have similarly suggested a benefit to selecting patients for combined
chemoradiation following induction chemotherapy53–55. Such an approach potentially
avoids radiation in patients who are destined to manifest metastatic disease, limiting local
therapy to those who are most likely to derive a benefit. One promising strategy for future
studies may be to build on this schedule of induction chemotherapy followed by
chemoradiation with the addition of targeted agents emerging from an improved
understanding of pancreatic cancer biology56–59.
We have demonstrated the feasibility of combining both 5-FU and gemcitabine with
radiation, with several long term survivors and a superior overall survival compared to
historical levels of eight to ten months. Although this regimen has achieved the pre-defined
goals of improving median survival beyond nine months with acceptable morbidity, the
observed median survival of 12 months is similar to the results of other recent phase II trials
in patients with locally advanced pancreatic cancer. Given the multiple other treatment
regimens that similarly appear to confer a 12-month median survival, we do not recommend
further study of this treatment combination in future trials.
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Overall Survival analyzed according to CA19-9 response
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Time to Progression analyzed according to CA19-9 response
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African American or Black 6(7%)
Asian 1(1%)
Age Mean (Std. Dev.) 62.3(9.8)
Performance Status 0 27(34%)
1 4 (58%)
2 6(8%)
Size (cm) Mean (Std. Dev.) 3.7(1.7)
Median (Range) 3.8(0 – 8.8)















Baseline CA19-9 Mean(Std. Dev.) 1288(2130)
Median(Range) 402(3,10854)
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Table 2
Survival and time to progression
Proportion Surviving 9 Months
Proportion 0.731
90% Lower Confidence Bound 0.64
Median Follow-up Time
N alive 4
Median (range) 55.2(38, 60) months
Overall Survival
N 78
Number Censored (%) 4 (5.1%)
Kaplan-Meier Estimate, 9-months (95% CI)9-
month Survival Estimate (95% CI)
0.73(0.62, 0.82)
Kaplan-Meier Estimate, 12-months (95%







Number Censored (%) 3 (3.8%)
3-month Survival Estimate (95%CI) 0.90(0.81, 0.95)
Kaplan-Meier Estimate, 9-months Survival
Estimate (95% CI)
0.54(0.42, 0.64)
Kaplan-Meier Estimate, 12-month Survival
Estimates (95% CI)
0.40(0.29, 0.50)
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Table 3







Blood / bone marrow 40(51) 10(13) 0
   Hemoglobin 6(8) 1(1) 0
   Total WBC 30(38) 6(8) 0
   Lymphopenia 20(26) 0 0
   Neutropenia 16(21) 7(9) 0
   Thrombocytopenia 11(14) 1 (1) 0
   Transfusion: platelets 1(1) 0 0
   Transfusion: pRBCs 4(5) 0 0
Non-hematological 47(60) 21(27) 2(3)
   Cardiovascular (general) 3(4) 1(1) 0
   Constitutional symptoms 17(22) 2(3) 0
   Gastrointestinal 29 (37) 3(4) 0
   Hemorrhage 2(3) 2(3) 1(1)
   Hepatic 7(9) 0 0
   Infection / febrile neutropenia 8(10) 0 1(1)
   Metabolic / laboratory 17(22) 2(3) 0
   Neurology 5(6) 0 0
   Pain 8(10) 1(1) 0
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